Miami, FL, Oct. 08, 2018 (GLOBE NEWSWIRE) --
Fuisz Pharma LLC (Fuisz) announced today the allowance of additional patent claims for its Film by Deposit Technology Platform.
Fuisz previously announced the issuance of US 9,901,545 (the “’545 Patent”) concerning the manufacture of oral thin film pharmaceuticals. The ‘545 Patent is entitled: “Method and composition for making an oral soluble film, containing at least one active agent.” The newly allowed claims, issued for U.S. Serial Number 15/866,729, are not yet available on the USPTO PAIR system.
Fuisz’ Film by Deposit Technology involves the manufacture of oral thin films by the deposit method, wherein the film is deposited in the well in which the film is formed. After drying, primary packaging is completed by the addition of a topsheet. Films made by deposit are not cast, but rather “poured” or deposited into the unit dose, primary packaging.
This approach offers important benefits over existing film methods, including a single process for manufacturing and packaging (as opposed to casting, slitting and converting), the elimination of active pharmaceutical ingredient loss, and precise dosing for the next generation of low dose drugs. The approach allows for novel formulations and shapes not commercially practicable with existing methods.
In the issued ‘545 patent, drug and film former solution are separately added to the well where the film is formed. In the newly allowed claims, drug and film former solution are deposited together into the well.
Fuisz Managing Member, Joseph Fuisz, remarked: “Our goal with this technology is to simplify film manufacture, and increase process yield. We’ve exceeded these goals with a new, patented methodology that also allows for novel formulations that cannot be made with existing methodologies. This enables new targets in film, not previously possible, and novel formulations that are not subject to copycat products. The allowed claims announced today substantially broaden the scope of patent protection for our Film by Deposit Technology. We are committed to further investing in this technology platform, and are actively prosecuting a continuation in part with additional improvements that relate to abuse diversion.”
Richard Fuisz, M.D., Founding Member of Fuisz (http://en.wikipedia.org/wiki/Richard_Fuisz), stated: “Now we have developed superior new methods and compositions of film that: are easier to manufacture, less costly, with more accurate dosing, simplified packaging, and forms which are designed to control abusive drugs, etc. I believe the technology presented in this patent application to be a hallmark achievement in the field of oral pharmaceutical dosage forms now and into the future. As with all that we do, this development reflects the craft work and different thinking that is our heritage from Prekmurje, Slovenia.”
Fuisz principals Richard Fuisz and Joseph Fuisz are long active in drug delivery systems. Richard Fuisz was the primary inventor of the Fuisz Technologies’ shearform matrix quick dissolve tablet (e.g. US 4,855,326). Richard and Joseph are inventors on the largest wet cast thin film drug delivery patent estate, which has been successfully employed to protect Suboxone® thin film from generic entrants (e.g. US 7,824,588). They also developed and patented a novel method of achieving sustained drug release in extruded sheets (US 8,613,285), which was acquired by a global consumer products company. They patented new ways of delivering botanical actives by films made through hot melt extrusion (US 9,125,434). And they developed a method of making monolayer films with bilayer functionality (US 8,617,589) acquired by a leading oral thin film company.
Fuisz Pharma LLC is a private pharmaceutical technology company originated by Joseph Fuisz (https://en.wikipedia.org/wiki/Joseph_Fuisz) and Richard Fuisz (https://en.wikipedia.org/wiki/Richard_Fuisz). The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies, as well as developing extruded sheet technology. The Fuiszes have extensive experience working with big and specialty pharma. Fuisz Pharma is also active in diagnostic systems including breath diagnostics. Fuisz Pharma has its headquarters in Miami. www.fuisz.com.